The short answer
Review ashwagandha before adding it to chlordiazepoxide. Some preparations can cause drowsiness, and official guidance notes possible sedative interactions.
What this answer covers
Oral Withania somnifera preparations; the cited sleep trial used a specific root extract, not arbitrary leaf or mixed products.
- Supplement or preparation
- Withania somnifera
- Medication ingredient
- chlordiazepoxide
Why product review is reasonable
NCCIH notes that ashwagandha can cause drowsiness and may interact with sedatives. This supports reviewing the specific extract alongside the medicine’s own alertness effects.
What the root-extract trial can tell us
A sleep trial reported improvement with its ashwagandha root extract, but no significant between-group difference in morning alertness. People taking regular medicines were excluded, so it did not test this combination.
Keep root and leaf products distinct
Bring the plant part, extract strength, dose and full blend label to the pharmacist. Neither the trial nor guidance provides a proven protective spacing interval.
Watch for impaired alertness
Chlordiazepoxide can affect alertness and coordination. Avoid driving if affected. Seek urgent help for severe difficulty waking or breathing, and tell the prescriber about alcohol, opioids and all other sedating products.
Evidence and practical considerations
Side effects & toxicity
Conditional alertness precaution is supported, without claiming every preparation causes sedation or a proven exact combination effect.
- Exact scope
- Oral Withania somnifera preparations; the cited sleep trial used a specific root extract, not arbitrary leaf or mixed products. with Exact oral chlordiazepoxide hydrochloride capsules. Long elimination half-life and slow decline after discontinuation; this label does not quantify St John’s wort enzyme induction. RxNorm IN 2356 relates to PIN 203173 hydrochloride, matching the labeled active ingredient. No combination product used.
- Medication form and route
- oral
- Timing or duration
- Source-specific single-dose, repeated-dose and observational exposures distinguished.
What remains uncertain
- Root-extract sleep trial excluded regular medication users and found no between-group morning-alertness difference; no exact co-use study.
Factors that may matter: preparation and plant part; clinical indication; dose; other medicines; baseline alertness.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral chlordiazepoxide.
Can impair alertness and coordination; other CNS depressants can increase impairment. Opioid combinations have a specific respiratory-depression warning. Dependence and withdrawal require supervised changes. Long elimination half-life and slow decline after discontinuation; this label does not quantify St John’s wort enzyme induction. RxNorm IN 2356 relates to PIN 203173 hydrochloride, matching the labeled active ingredient. No combination product used.
How this applies: Exact IN and labeled oral formulation; route, salt and metabolite distinctions retained.
No quantified risk for every herb or universal protective spacing interval. Opioid-specific evidence does not prove equal botanical respiratory risk.
Source 2: official guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: People considering the specified supplement.
Some preparations can cause drowsiness; possible interaction with sedatives. Products and studied preparations vary.
How this applies: Preparation-specific context; not a directly measured chlordiazepoxide interaction.
No direct chlordiazepoxide study; short-term safety observations do not establish long-term safety.
Source 3: randomized placebo-controlled trial
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 60 adults enrolled with insomnia and anxiety.
Some sleep outcomes improved; no adverse events were reported. Morning alertness did not differ significantly between groups at ten weeks.
How this applies: Original named medication and preparation only; indirect evidence for chlordiazepoxide. Comparator arms are not coadministration.
Regular medication users and people with restless legs syndrome or other sleep disorders were excluded. Exploratory study; internal reporting inconsistencies in analysis counts. Cannot extend to chlordiazepoxide-treated patients or leaf preparations.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Current exact available claims adjudicated using original captures and explicit identity and comparator limits. | |
| Research summary published |
Article revision: ef227211518372c3
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.